T-cell lymphoma unspecified with cutaneous manifestations of erythroderma: A clinical case
https://doi.org/10.34215/1609-1175-2024-2-79-82
Abstract
Nodal peripheral T-cell lymphomas (PTCL) represent a rare group of lymphoproliferative diseases, with mature (postthymic) activated T lymphocytes as the substrate. Within this group of lymphomas, the most common subtype is peripheral T-cell lymphoma, unspecified. In this article, a clinical case of erythroderma in cutaneous T-cell lymphoma is described. Based on the medical history, clinical picture, and laboratory examination results, the patient was diagnosed with T-cell lymphoma, unspecified with cutaneous manifestations of erythroderma. The analysis of two lines of therapy, including targeted therapy, is also presented.
About the Authors
M. I. Babkova
Regional Dermatology and Venereology Dispensary
Russian Federation
Russian Federation
Maria I. Babkova, Head of the Dermatovenereology Department
5 Angarskaya st., Khabarovsk, 680003
+7 (929) 411-88-06
S. K. Batalova
Regional Dermatology and Venereology Dispensary
Russian Federation
Russian Federation
Khabarovsk
A. A. Lvova
Regional Dermatology and Venereology Dispensary; Institute for Advanced Studies
Russian Federation
Russian Federation
Khabarovsk
References
1. Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, Bouabdallah R, Berger F, Delmer A, Coiffi er B, Reyes F, Gaulard P; Groupe d’Etude des Lymphomes de l’Adulte (GELA). Prognostic signifi cance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecifi ed: A Groupe d’Etude des Lymphomes de l’Adulte (GELA) study. Blood. 2006;108(13):4163–9. doi: 10.1182/blood-2006-04-017632
2. Th e Non-Hodgkin’s Lymphoma Classifi cation Project. A clinical evaluation of the International Lymphoma Study Group classifi cation of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909–18. doi: 10.1182/blood.V89.11.3909
3. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, Meijer CJ, Willemze R. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653–61. doi: 10.1182/blood.V95.12.3653
4. The Non-Hodgkin’s Lymphoma Classifi cation Project. A clinical evaluation of the International Lymphoma Study Group classifi cation of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909–18. doi: 10.1182/blood.V89.11.3909
5. International T-cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology fi ndings and clinical outcomes. J. Clin. Oncol. 2008;26(25):4124–30. doi: 10.1200/JCO.2008.16.4558
6. Newland KM, McCormack CJ, Twigger R, Buelens O, Hughes CF, Lade S Dickinson M, Yap LM, Ryan G, Prince HM. Th e effi cacy of methtotrexate for lymphomatoid papulosis. J Am Acad Dermatol. 2015;72(6):1088–90. doi: 10.1016/j.jaad.2015.03.001
7. Gorenkova LG, Kravchenko SK, Belousova IE. Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation. Vestnik Dermatologii i Venerologii. 2019;95(2):42–49 (In Russ.)]. doi: 10.25208/0042-4609-2019-95-2-42-49
8. Enos TH, Feigenbaum LS, Wickless HW. Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data. Int J Dermatol. 2017;56(12):1400–5. doi: 10.1111/ijd.13696
9. Pai AH, George A, Adiga D, Girisha BS. Peripheral T cell lymphoma: not otherwise specifi ed. Indian J Dermatol. 2015;60(2):215.
Review
For citations:
Babkova M.I., Batalova S.K., Lvova A.A. T-cell lymphoma unspecified with cutaneous manifestations of erythroderma: A clinical case. Pacific Medical Journal. 2024;(2):79-82. (In Russ.) https://doi.org/10.34215/1609-1175-2024-2-79-82
Views:
603
Email this article 